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A B S T R A C T
Background
Pharmacological treatments have been successfully used to treat Generalized Anxiety Disorder (GAD). Benzodiazepine and non
benzodiazepine anxiolytics used to be the mainstay for the pharmacological treatment of GAD. However, data emerging over the last
two decades have shown that antidepressants may be as effective as anxiolytics in this condition. The use of antidepressants may also
be beneficial , because GAD often coexists with major depressive disorder (62% comorbidity) and dysthymia (37%).
Objectives
To assess the efficacy and acceptability of antidepressants for treating generalized anxiety disorder.
Search methods
Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register - CCDANCTR (up to May 2002), Anxiety
Neurosis (up to May 2002) and Cochrane Controlled Trials Register (CENTRAL/CCTR) (up to May 2002), MEDLINE (1966 to
May 2002), LILACS (1982 to May 2002); reference searching; personal communication; conference abstracts and book chapters on
the treatment of generalized anxiety disorder.
Selection criteria
Randomized controlled trials were included. Non randomized studies and those that included patients with both GAD and another
Axis I co-morbidity were excluded.
Data collection and analysis
The data from studies were extracted independently by two reviewers. Relative risks, weighted mean difference and number needed to
treat were estimated. People who died or dropped out were regarded as having had no improvement.
Main results
Antidepressants (imipramine, venlafaxine and paroxetine) were found to be superior to placebo in treating GAD. The calculated NNT
for antidepressants in GAD is 5.15. Dropout rates did not differ between antidepressants. Only one study presented data on imipramine
and trazodone. Imipramine was chosen as the reference drug and, therefore, data on trazodone could not be included in the meta
analysis. Only one study was conducted among children and adolescents (Rynn 2000). This showed very promising results of sertraline
in children and adolescents with GAD, which warrants replication in larger samples.
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Authors’ conclusions
The available evidence suggests that antidepressants are superior to placebo in treating GAD. There is evidence from one trial suggesting
that paroxetine and imipramine have a similar efficacy and tolerability. There is also evidence from placebo-controlled trials suggesting
that these drugs are well tolerated by GAD patients. Further trials of antidepressants for GAD will help to demonstrate which
antidepressants should be used for which patients.
P L A I N L A N G U A G E S U M M A R Y
Antidepressants for generalized anxiety disorder (GAD)
In the past, people with generalized anxiety disorder (GAD) were usually treated with drugs designed to reduce anxiety (called
anxiolytics). There is growing evidence that drugs used to treat depression (antidepressants) may also be helpful for people with GAD.
We therefore reviewed clinical trials of the use of antidepressants in GAD . Fifteen published trials were included. Of these trials, eight
used recognized methods for diagnosing GAD and gave useful data (Rickels 1993; Rocca 1997; Davidson 1999 a; Gelenberg 2000,
Rickels 2000 b, Hackett 1999, Pollack 2001, Rynn 2000). Six trials were excluded: two trials were open studies, without a control group
(Hedges 1996; Wingerson 1992); two included patients with GAD plus other types of mental illness (Johnstone 1980 a; Lipman 1986);
one study included patients who were stopping long term benzodiazepine therapy (Rickels 2000 a). One study presented early data
for an already included study (Hackett 1999). We are waiting for further data for one study (Hoehn-Saric 1988). One study involved
children and adolescents with GAD (Rynn 2000) and its results were reviewed separately. Our review showed that antidepressants were
better than placebo (dummy treament) for treating GAD and were well tolerated. We did not find evidence to conclude whether some
types of antidepressant are better than others. Overall, about 5 people need to be treated in order for one person with GAD to benefit.
The single study using antidepressants in children and adolescents with GAD also showed very promising results.
B A C K G R O U N D
Generalized anxiety disorder (GAD) is characterized by exces-
sive, pervasive and uncontrollable worry. Associated symptoms
include irritability, restlessness and concentration problems. So-
matic symptoms of GAD include muscle tension, sweating, dry
mouth, nausea and diarrhea (APA 1994). GAD is a chronic and
recurrent disorder with a low rate of remission (Yonkers 1996).
GAD has a considerable impact on quality of life and is associated
with increased reliance in public assistance, impaired social life
and low ratings of life satisfaction (Massion 1993). The current
and lifetime prevalence of GAD have been estimated to be 1.6%
and 5.1% respectively (Wittchen 1994). The lifetime prevalence
of psychiatric comorbidities in GAD patients can reach over 90
% (Wittchen 1994). The most common co-morbidities are ma-
jor depressive disorder (62%) and dysthymia (39%) (Judd 1998).
However, recent epidemiological data suggests that the impact
of comorbidity in clinical outcomes is no greater in GAD than
in other anxiety disorders (Hunt 2002). Moreover, comorbidities
such as major depression do not appear to change the course of
GAD (Hunt 2002).
Benzodiazepines and non benzodiazepine anxiolytics such as bus-
pirone have been the mainstay for the treatment of GAD in the
past (Brawman-Mintzer 2001). As GAD tends to be a chronic
condition, long-term pharmacological treatment is often neces-
sary. This raises concern about the use of benzodiazepines, since
these compounds may be associated with risks of abuse and de-
pendence. Buspirone is devoid of the dependence risks associated
with benzodiazepines, however it has a more limited spectrum of
efficacy and delayed onset of action compared to other treatments.
A variety of psychotherapeutic approaches have been used to treat
GAD. To date, the most consistent data on the psychotherapy of
GAD comes from the cognitive-behavioural therapy (CBT) ap-
proach. Results from well-conducted trials suggest that CBT can
produce clinically relevant and long term therapeutic improve-
ments compared with controls. Psychotherapeutic approaches also
seem to be well tolerated by patients and the dropout rates in clin-
ical trials are low (Borkovec 2001). There are also data supporting
the notion that psychotherapy may have an additional impact in
the comorbid conditions associated to GAD (Borkovec 2001).
The first trial assessing the effect of antidepressants in GAD, diag-
nosed according to DSM-III criteria, was conducted by Hoehn-
Saric and his colleagues (Hoehn-Saric 1988). These authors com-
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pared alprazolam and imipramine in a group of 52 GAD pa-
tients. They showed that both drugs were effective in treating
GAD. However, imipramine was more effective in attenuating
psychological symptoms such as dysphoria and anticipatory neg-
ative thinking, whereas alprazolam was more effective in somatic
symptoms and in the hyperarousal associated with GAD. The same
trend was detected by Rickels and his colleagues (Rickels 1993)
in a comparison between imipramine, trazodone, diazepam and
placebo. Rickels (Rickels 1993) showed that from week 3 through
week 8, trazodone achieved similar anxiolytic efficacy to diazepam;
the effect of imipramine was found to be somewhat better, and
psychological symptoms such as apprehension and worry respond-
edbetter to the antidepressants than the anxiolytics. A study by
Rocca and associates (Rocca 1997), within a sample of DSM-IV
diagnosed GAD patients, supported the theory that antidepres-
sants affect predominantly psychological symptoms whereas ben-
zodiazepine affect predominantly somatic symptoms in GAD. A
comparison between antidepressants and non benzodiazepine anx-
iolytics is available only for venlafaxine and buspirone (Davidson
1999 a). This study included 365 patients and showed that ven-
lafaxine and buspirone were superior to placebo in the majority of
outcomes considered. There is also evidence that the management
of benzodiazepine discontinuation in GAD patients can be facil-
itated by co-prescribing imipramine but not buspirone (Rickels
2000 a).
In the light of the data presented, there are reasons to believe that
antidepressants may offer a valuable alternative in the treatment
of GAD patients. In the present review, RCT data on the use
of antidepressants for treating GAD were assessed. The present
review is part of a series of reviews on GAD treatment:
In the light of the data presented, there are reasons to believe that
antidepressants may offer a valuable alternative in the treatment
of GAD patients. In the present review, RCTs data on the use
of antidepressants for treating GAD will be assessed. The present
review is part of a series of reviews on GAD treatment. The other
reviews in the series are:
(1) Antidepressants
(2) Buspirone and other azapirones
(3) Benzodiazepines
(4) Psychotherapy.
O B J E C T I V E S
To investigate the efficacy and acceptability of antidepressants in
the treatment of generalized anxiety disorder.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All relevant randomised controlled trials comparing antidepres-
sants to placebo or to another active pharmacological treatment.
Types of participants
People with a diagnosis of generalized anxiety disorder irrespective
of gender, race, age or nationality.
Exclusion criteria: patients with generalized anxiety disorder and
another axis I co-morbidity.
Types of interventions
1) Any type of antidepressant
2) Control treatments (any active drug or placebo). Whenever a
placebo arm was present in the study, the comparison included in
the metanalysis was antidepressant vs placebo.
Types of outcome measures
Primary outcomes of interest were:
1) Generalized anxiety changes at the end of trial
(a) absence of treatment response as defined in the studies (treat-
ment response is defined as absence of sufficient symptoms to meet
diagnostic criteria for generalized anxiety disorder); scores of 1 or
2 in the Clinical Global impression Scale, which is a continuous
scale of seven grades, where 1= very much improved, 2 = much
improved... and 7 = very much worse
2) Acceptability of the treatment as measured by:
(a) the number of people dropping out during the trial, and post
randomisation exclusions
(b) specific side-effects.
Search methods for identification of studies
1. Electronic databases:
The following electronic databases were searched:
- The Cochrane Collaboration Depression, Anxiety and Neurosis
Controlled Trials Register (CCDANCTR) up to May 2002;
- The Cochrane Central Register of Controlled Trials (CEN-
TRAL) (previously CCTR);
- MEDLINE (1966-May2002)
- LILACS (1982-May 2002)
The MEDLINE and LILACS (up to May 2002) searches also
acted as a quality assessment whereby the comprehensiveness and
completeness of the two Cochrane registers were evaluated.
The terms used in the search were: anxiety or anxiety disor-
der and pharmacotherapy-5ht or pharmacotherapy-ad or pharma-
cotherapy-maoi or pharmacotherapy-nari or pharmacotherapy-
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rima or pharmacotherapy-r-ssri or pharmacotherapy-r-tca or phar-
macotherapy-snri or pharmacotherapy-ssri or pharmacotherapy-
tca.
2. Conference abstracts were searched for references.
3. Personal communication: in order to ensure that as many as
possible RCTs would be identified, the authors of the included
studies were consulted to find out if they knew of any published or
unpublished RCTs/ CCTs of pharmacological treatment of gen-
eralized anxiety disorder, and which were not yet identified. A list
of all identified RCTs identified through consulting other sources
was sent to the authors.
4. Attempts were made to obtain unpublished trials from the phar-
maceutical industry.
5. Book chapters on treatment of generalized anxiety disorder were
reviewed.
Data collection and analysis
Selection of trials
One reviewer (FK) screened the abstracts of all publications that
were obtained by the search strategy. A distinction was made be-
tween:
1) eligible studies, in which antidepressants were compared to
placebo or another drug
2) studies without any control element; studies of general treat-
ment for GAD rather than pharmacological; studies of drug treat-
ments other than antidepressants
For abstracts where the authors found any indication of a clinical
trial, the full article was obtained and inspected to assess its rele-
vance to this review.
Quality assessment
In order to ensure that variation was not caused by systematic
errors in the design of a study, the methodological quality of the
selected trials was assessed by two independent reviewers (FK and
RS). The methodological quality was assessed using the criteria
described in the Cochrane Handbook (Clarke 2000). It is based
on the evidence of a strong relationship between the potential for
bias in the results and the allocation concealment and is defined
as below:
A. Low risk of bias (adequate allocation concealment)
B. Moderate risk of bias (unclear method of allocation conceal-
ment )
C. High risk of bias (inadequate allocation concealment)
For the purpose of the analysis in this review, trials were included
if they met the criteria A or B as described in the Cochrane Hand-
book.
Data Management
Data were independently extracted by two reviewers (FK and RS).
Any disagreement was discussed with a third reviewer (MSL), de-
cisions were documented and, where necessary, the study authors
contacted to resolve the issue. All exclusions/dropouts were iden-
tified. If no information was available (either from the report or
the authors) it was assumed that dropouts were due to side effects/
treatment failure.
Analysis
In the statistical analysis, the relative risk and 95% confidence in-
terval for dichotomous variables were calculated using the random
effects model, as it takes into account of any between study differ-
ences (even if there is no statistically significant heterogeneity) and
gives the same result as the fixed effects model when there is no
between-study variance. Review Manager Software 4.1was used to
analyse the results. In the efficacy analysis, the number needed to
treat (NNT) was also calculated, using 95% confidence intervals.
The NNT is defined as the inverse of differences of risk between
groups. The NNT expresses the number of patients that have to
be treated in order to achieve oneresponse, when compared to the
control group.
R E S U L T S
Description of studies
Search
We retrieved 15 clinical trials in which antidepressants were used
to treat GAD.
- Eight trials assessing antidepressants in adult GAD patients used
diagnostic criteria for GAD and had data that could be included
in this review (2058 patients in total). One trial was conducted
among children, so these results were handled separately and not
included in the “all antidepressants” (Rynn 2000). One additional
report presented preliminary data for an already included study
(Hackett 1999). We included the following trials in the meta
analysis: Rickels 1993, Rocca 1997, Davidson 1999 a, Gelenberg
2000, Rickels 2000 b, Hackett 1999 and Pollack 2001. In one
trial, just one variable (side-effects), was described in a way which
permitted inclusion in the meta-analysis (Rickels 2000 b); further
information from the authors is awaited in order to include other
outcomes.
- Five trials were excluded: two studies were open trials (Hedges
1996; Wingerson 1992); two studies (Johnstone 1980 a; Lipman
1986) included patients who fulfilled criteria for more than one
diagnostic category (depressive neurosis and hysterical or phobic
neurosis); one study included patients who were discontinuing
long term benzodiazepine therapy at the time the trial was con-
ducted (Rickels 2000 a).
- One study is still awaiting assessment because the data required
for this review were not available in the published version (Hoehn-
Saric 1988).
Design
All the included studies were described as randomised and used
a parallel group design. The duration of the trials ranged from 6
weeks (Hoehn-Saric 1988) to 28 weeks (Gelenberg 2000). Two
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studies included a long term follow up after the acute phase of
treatment (Gelenberg 2000, Hackett 1999) All studies used inac-
tive placebo groups.
Setting
All included trials were conducted in the US, except Rocca 1997,
conducted in Italy and Hackett 1999, conducted in several coun-
tries in Europe. All trials studied outpatients from psychiatric clin-
ics or from the community.
Participants
All trials included for the main comparisons used DSM-III, DSM-
III-R or DSM-IV criteria for the diagnosis of GAD. The study
populations were reasonably comparable. The number of partici-
pants randomised in the trials ranged from 56 to 541.
Outcomes
All trials used symptom scales in assessing treatment effects. The
Hamilton Anxiety Scale (HAM-A) was the most commonly used.
However, some trials lacked data on standard deviations, and in
other cases showed skewed data distribution. Continuous out-
comes will be analysed in future versions of this review, when fur-
ther information from the authors are obtained.
Three dichotomous outcomes were used in this review:
(1) absence of response: for most trials this equated to a Clinical
Global Impression (CGI) score of 1 or 2;
(2) dropout rate;
(3) specific side effects.
Reason for excluding studies
Some of the excluded studies were not randomized and some were
conducted using patients with an Axis I disorder in addition to
GAD.
Risk of bias in included studies
All RCTs were classified as ’B’, not giving information on alloca-
tion concealment. We are still awaiting further details from most
of the authors.
All trials reported the randomization procedure without any infor-
mation on allocation concealment. Although many trials reported
an intention-to-treat analysis, some of them excluded patients af-
ter randomization because of protocol violations. The omission of
standard deviations was also common
Effects of interventions
Efficacy
All antidepressants vs placebo:
The efficacy analysis included the following studies, where data
could be extracted: Rickels 1993, Davidson 1999 a, Gelenberg
2000 and Pollack 2001. Other included studies were used in the
analysis of number of dropouts and specific side effects.
In general, short-term treatment response was more likely in pa-
tients receiving antidepressants than placebo. One study (Rickels
1993) compared treatments (imipramine, trazodone, diazepam
and placebo). As imipramine was considered a reference antide-
pressant, we used the ’imipramine vs placebo’ comparison rather
than ’trazodone vs placebo’. Considering all trials, the pooled RR
for non treatment response was 0.70 (95% CI 0.62-0.79), favour-
ing antidepressant treatment. The calculated NNT was 5.5 (95%
CI 4.1-8.4) for a non-response rate of 62% in the placebo group.
- Imipramine (Rickels 1993): The calculated RR was 0.67 (95 %
CI 0.50-0.91) and the NNT was 4.0 (95% CI 2.4-13.7).
- Venlafaxine (Davidson 1999 a, Gelenberg 2000): The calculated
RR for non treatment response was 0.68 (95% CI 0.46-0.99), and
the NNT was 5.0 (95% CI 3.58-8.62) for a non-response rate of
66% in the placebo group. The studies carried out by Rickels 2000
b and Hackett 1999could not be used for the efficacy analysis, as
data could not be extracted as reported.
- Paroxetine (Pollack 2001): The calculated RR for non treatment
response was 0.72 (95% CI 0.56-0.92), and the calculated NNT
was 6.72 (95% CI 3.9-24.7)
- Paroxetine vs imipramine (Rocca 1997): The calculated RR was
1.73 (95% CI 0.31-9.57)
Sertraline vs placebo in children and adolescents:
- Sertraline (Rynn 2000): This study was not included in the meta
analysis because it studied children and adolescents. The results
obtained in this small trial (N = 22) were very compelling, showing
a calculated NNT of 1.22 (0.90-1.7).
Acceptability
Dropouts:
No significant differences were found between antidepressants and
placebo. The RR for any antidepressant was 0.95 (95% CI 0.84-
1.09). Similarly, when individual antidepressants were considered,
no differences were found between individual treatments and the
placebo group:
-Imipramine: RR = 0.71 (95% CI 0.41-1.24);
- Venlafaxine: RR = 0.86 (95% CI 0.72-1.02);
- Sertraline: RR = 0.45 (95% CI 0.03-5.84)
- Paroxetine: RR = 1.15 (95% CI 0.74 - 1.78) and
- Paroxetine vs imipramine: RR = 1.62 (95% CI 0.58 - 4.48)
Common drug specific side effects:
Overall, side effects were more common in the drug treated than
in the placebo treated groups. Data for more than one trial were
available only for venlafaxine:
- Venlafaxine (Davidson 1999 a, Gelenberg 2000): those taking
venlafaxine were more likely to report nausea, dry mouth, insom-
nia, constipation, somnolence, anorexia, sexual dysfunction and
flatulence.
D I S C U S S I O N
Efficacy
The present review showed the efficacy of antidepressants in the
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treatment of GAD. These results were obtained when drugs with
differential profiles such as imipramine and venlafaxine were com-
pared to placebo. The calculated NNT for these antidepressants
as a group, was 5.54. This means that about 6 patients have to be
treated to cause one additional clinical improvement.
Imipramine showed a smaller NNT (4.07, 95% CI 2.39 to 13.74)
than venlafaxine = 5.06 (95% CI 3.6 to 8.6) and paroxetine =
6.7 (95% CI 3.9 or 24.7). However, this does not allow for the
conclusion that the effect size of imipramine is larger.Only one
study compared an SSRI (paroxetine) to imipramine, and similar
results were found for the efficacy assessment and acceptability.
The available evidence clearly suggests that antidepressants are bet-
ter than placebo. No study using active placebo groups was con-
ducted in GAD patients. This leaves unanswered questions about
whether patients may be aware that they are receiving an active
drug, and whether it is this that might be responsible for beneficial
effect in the treated groups. The idea that antidepressants may im-
prove both symptoms of depression and anxiety is not a new one
(Johnstone 1980 a). However, this review was conducted using
studies which included patients with GAD without concurrent
major depression or other Axis I comorbidities. This allows us to
conclude that the anxiolytic effect of antidepressants in GAD is
independent from its effect on major depression and dysthymia.
Only one study assessed the use of antidepressants among chil-
dren and adolescents (Rynn 2000). This study included a small
sample of patients (N=22) and, therefore, results should be viewed
with caution. However, the effect size obtained was very robust,
which suggests that younger patients may have a more favourable
response than adults.
Acceptability
Overall, the number of patients dropping out of studies was similar
in the antidepressant and placebo groups. Newer antidepressants
such as venlafaxine and paroxetine usually have a better accept-
ability profile than tricyclics. However, there was no difference be-
tween the tricyclic imipramine and the new antidepressants (ven-
lafaxine and paroxetine) in terms of dropouts, which is, perhaps,
the most robust indicator of acceptability. Again, a direct com-
parison between venlafaxine and imipramine in terms of accept-
ability is lacking. Some insight into this question can be drawn
from the study conducted by Rocca 1997, which allowed a direct
comparison between imipramine and the selective serotonin reup-
take inhibitor (SSRI) paroxetine. In the latter study, similar rates
of dropouts were reported, adding to the notion that acceptability
may not vary as much as one might expect when newer, and sup-
posedly better tolerated drugs, are compared to the tricyclics. The
study conducted by Rocca 1997cannot be used as a final argument
in favour of an equal acceptability between tricyclics and SSRIs as
the sample size of this study was rather small (25 patients allocated
to paroxetine and 18 patients allocated to imipramine), resulting
in the possibility of a type II error. However, the study conducted
by Rocca 1997 is consistent with the side effect profile expected
for these two classes of drugs. Paroxetine was associated with sig-
nificantly more reports of nausea whereas imipramine was asso-
ciated with more anti-cholinergic side effects such as dry mouth,
constipation and drowsiness.
Generalisability of findings
The present review included only GAD patients without concur-
rent Axis I co-morbidities. This is a strength in terms of the gen-
eralisability of the findings for ’pure GAD’ patients. However, if
one considers that nearly all people (around 90%) with GAD also
have psychiatric co-morbidities (Wittchen 1994), one should be
cautious in translating findings obtained in such an specific (and
unusual) population into clinical practice. However, the two ma-
jor co-morbidities of GAD are major depression and dysthymia,
both of which are known to be treatable with antidepressants.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The available evidence suggests that imipramine, venlafaxine and
paroxetine are superior to placebo in treating GAD in adults. Ser-
traline has been shown to be superior to placebo in treating GAD
in children and adolescents. It was not possible to assess differ-
ences in efficacy between imipramine and venlafaxine or venlafax-
ine and paroxetine, as no direct comparison between these drugs
was carried out. There is evidence from one trial suggesting that
paroxetine and imipramine are similar in terms of efficacy and
tolerability. Dropout rates were not significantly different between
antidepressant and placebo groups which suggests that antidepres-
sants are well tolerated.
Implications for research
The efficacy of antidepressants such as imipramine, venlafaxine
and paroxetine in treating GAD raises the question of whether
other antidepressants would be equally useful. Data emerging
from open trials suggest that nefazodone (Hedges 1996) and
clomipramine (Wingerson 1992) may be useful choices in GAD
patients. However, in one of the excluded trials, clomipramine
showed a very high dropout rate within the first weeks of treatment
(Wingerson 1992), which might indicate that potent serotoner-
gic effects may be unacceptable to patients suffering from GAD.
Further trials using antidepressants in the treatment of GAD will
help to demonstrate which antidepressants could be a reasonable
choice in the treatment of these patients. Another important re-
search question is whether the long-term efficacy described for
venlafaxine (Gelenberg 2000, Hackett 1999) also applies to other
antidepressants. Finally, studies designed to compare efficacy and
acceptability of different antidepressants; antidepressants versus
6Antidepressants for generalised anxiety disorder (GAD) (Review)
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anxiolytics; antidepressants versus specific forms of psychotherapy;
and the advantages and disadvantages of the combination of these
treatments will help to better define the role of antidepressants in
the treatment of GAD.
A C K N O W L E D G E M E N T S
We would like to thank the valuable help provided by Luciano
Isolan, João Vicente Busnello and João Quevedo in carrying out
the initial part of this study.
R E F E R E N C E S
References to studies included in this review
Davidson 1999 a {published data only}
∗ Davidson JR, DuPont RL, Hedges D, Haskins JT. Efficacy,
safety, and tolerability of venlafaxine extended release and
buspirone in outpatients with generalized anxiety disorder.
Journal of Clinical Psychiatry 1999;60(8):528–35.
Gelenberg 2000 {published data only}
Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins
JT, Salinas E. Efficacy of venlafaxine extended-release
capsules in nondepressed outpatients with generalized
anxiety disorder. JAMA 2000;283(23):3082–8.
Meoni P, Salinas E, Brault Y, Hackett D. Pattern of symptom
improvement following treatment with venlafaxine XR
in patients with generalized anxiety disorder. Journal of
Clinical Psychiatry 2001;62(11):888–93.
Hackett 1999 {published data only}
∗ Allgulander C, Hackett D, Salinas E. Venlafaxine extended
release (ER) in the treatment of generalized anxiety disorder.
British Journal of Psychiatry 2001;179:15–22.
Hackett D, Desmet A, Salinas EO. Dose-response efficacy
of long-term treatment of venlafaxine extended-release in
generalized anxiety disorder. Journal of the European College
of Neuropsychopharmacology 9[Suppl 5], 315. 1999 1999;9
(Suppl 5):315.
Hackett D, Salinas E. A six-month evaluation of three dose
levels of venlafaxine extended-released in nondepressed
outpatients with GAD. 152nd Annual Meeting of the
American Psychiatric Association. Washington DC, USA.
15 20th May. 1999.
Meoni P, Salinas E, Brault Y, Hackett D. Pattern of symptom
improvement following treatment with venlafaxine XR
in patients with generalized anxiety disorder. Journal of
Clinical Psychiatry 2001;62(11):888–93.
Pollack 2001 {published data only}
Pollack MH, Zaninelli R, Goddard A, McCafferty JP, Bellew
K, Burnham DB, et al. Paroxetine in the treatment of
generalized anxiety disorder: results of a placebo-controlled,
flexible-dosage trial. Journal of Clinical Psychiatry 2001;62
(5):350–7.
Rickels 1993 {published data only}
∗ Rickels K, Downing R, Schweizer E, Hassman H.
Antidepressants for the treatment of generalized anxiety
disorder. A placebo-controlled comparison of imipramine,
trazodone, and diazepam. Archives of General Psychiatry
1993;50(11):884–95.
Rickels 2000 b {published data only}
Meoni P, Salinas E, Brault Y, Hackett D. Pattern of symptom
improvement following treatment with venlafaxine XR
in patients with generalized anxiety disorder. Journal of
Clinical Psychiatry 2001;62(11):888–93.
Rickels K, Pollack MH, Sheehan DV, Haskins JT. Efficacy
of extended release venlafaxine in nondepressed outpatients
with generalized anxiety disorder. American Journal of
Psychiatry 2000;157(6):968–74.
Rocca 1997 {published data only}
Rocca P, Fonzo V, Scotta M, Zanalda E, Ravizza L.
Paroxetine efficacy in the treatment of generalized anxiety
disorder. Acta Psychiatrica Scandinavica 1997;95(5):
444–50.
Rynn 2000 {published data only}
Rynn M, Siqueland L, Rickels K, Garcia Espana F.
Treatment outcome of children with anxiety disorders.
39th Annual Meeting of the American College of
Neuropsychopharmacology; Dec 10-14; San Juan; Puerto
Rico. 2000.
Rynn MA, Siqueland L, Rickels K. Placebo-controlled trial
of sertraline in the treatment of children with generalized
anxiety disorder. American Journal of Psychiatry 2001;158
(12):2008–14.
References to studies excluded from this review
Hedges 1996 {published data only}
∗ Hedges DW, Reimherr FW, Strong RE, Halls CH, Rust
C. An open trial of nefazodone in adult patients with
generalized anxiety disorder. Psychopharmacology Bulletin
1996;32(4):671–6.
7Antidepressants for generalised anxiety disorder (GAD) (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Johnstone 1980 a {published data only}
Frith CD, Stevens M, Johnstone EC, Owens DG. The
effects of chronic treatment with amitriptyline and
diazepam on electrodermal activity in neurotic outpatients.
Physiological Psychology 1984;12(3):247–52.
Johnstone EC, Bourne RC, Crow TJ, Frith CD, Gamble
S, Lofthouse R, et al. The relationships between clinical
response, psychophysiological variables and plasma levels
of amitriptyline and diazepam in neurotic outpatients.
Psychopharmacology 1981;72(3):233–40.
Johnstone EC, Owens DG, Frith CD, McPherson K, Dowie
C, Gold A. Neurotic Illness and its response to anxiolytic
and antidepressant treatment. Psychological Medicine 1980;
10(2):321–8.
Lipman 1986 {published data only}
Kahn RJ, McNair DM, Lipman RS, Covi L, Rickels K,
Downing R, et al. Imipramine and Chlordiazepoxide
in depressive and anxiety disorders. Archives of General
Psychiatry 1986;43(1):79–85.
Lipman RS, Covi L, Rickels K, McNair DM, Downing
R, Kahn RJ, et al. Imipramine and chlordiazepoxide in
depressive and anxiety disorders. I. Efficacy in depressed
outpatients. Archives of General Psychiatry 1986;43(1):
68–77.
Rickels 2000 a {published data only}
Rickels K, DeMartinis N, Garcia-España F, Greenblatt
DJ, Mandos LA, Rynn M. Imipramine and buspirone in
treatment of patients with generalized anxiety disorder
who are discontinuing long-term benzodiazepine therapy.
American Journal of Psychiatry 2000;157(12):1973–9.
Wingerson 1992 {published data only}
Wingerson D, Nguyen C, Roy-Byrne PP. Chlomipramine
treatment for generalized anxiety disorder. Journal of
Clinical Psychopharmacology 1992;12(3):214–5.
References to studies awaiting assessment
Hoehn-Saric 1988 {published data only}
Hoehn-Saric R, McLeod DR, Zimmerli WD. Differential
effects of alprazolam and imipramine in generalized anxiety




American Psychiatric Association. Diagnostic and Statistical
manual of mental disorders: DSM-IV. Washington DC:
American Psychiatric Association, 1994.
Berrios 1995
Berrios GE, Link C. Anxiety disorders - clinical section. A
history of clinical psychiatry. London: Atlone, 1995:545–62.
Borkovec 2001
Borkovec TD, Ruscio AM. Psychotherapy for generalized
anxiety disorder. Journal of Clinical Psychiatry 2001;62
(Suppl 11):15–9.
Brawman-Mintzer 2001
Brawman-Mintzer O. Pharmacological treatment of
generalized anxiety disorder. Psychiatric Clinics of North
America 2001;24(1):119–37.
Clarke 2000
Clarke M, Oxman AD. Cochrane Reviewers’ Handbook.
Oxford: Update Software, 2000.
Hackett 2000
Hackett D. Venlafaxine XR in the treatment of anxiety. Acta
Psychiatrica Scandinavica. Supplementum 2000;406:30–5.
Hunt 2002
Hunt CJ. The current status of the diagnostic validity and
treatment of generalized anxiety disorder. Current Opinion
in Psychiatry 2002;15(2):157–62.
Judd 1998
Judd LL, Kessler RC, Paulus MP. Comorbidity as a
fundamental feature of generalized anxiety disorders: results
form the National Comorbidity Survey (NCS). Acta
Psychiatrica Scandinavica, Supplementum 1998;393:6–11.
Kendell 1995
Kendell RE. The role of diagnosis in psychiatry. Oxford:
Blackwell, 1975:67–8.
Massion 1993
Massion AO, Warshaw MG, Keller MB. Quality of life
and psychiatric morbidity in panic disorder and generalized
anxiety disorder. American Journal of Psychiatry 1993;150
(4):600–7.
Wittchen 1994
Wittchen HU, Zhao S, Kessler RC, Eaton WW. DSM-III-
R generalized anxiety disorder in the national comorbidity
survey. Archives of General Psychiatry 1994;51(5):355–64.
Yonkers 1996
Yonkers KA, Warshaw MG, Massion AO, Keller MB.
Phenomenology and course of generalized anxiety disorder.
British Journal of Psychiatry 1996;168:308–13.
∗ Indicates the major publication for the study
8Antidepressants for generalised anxiety disorder (GAD) (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S




3. Four parallel groups (placebo, venlafaxine 75 mg/d, venlafaxine 150 mg/d, buspirone
30 mg/d)
4. Duration: 8 weeks
5. Analysis: LOCF
Participants 1. Diagnosis: GAD (DSM-IV)
2. N = 405
3. Age (mean and SD):
placebo = 39 (11)
venlafaxine 75 mg/d = 38(10)
venlafaxine 150 mg/d = 37 (11)




excluded any significant psychiatric disorder other than GAD
Interventions 1. Placebo (N = 98)
2. Venlafaxine 75 mg/d (N = 87)
3. Venlafaxine 150 mg/d (N = 97)
Outcomes 1. dropout rates
2. CGI scores
3. HAM -A endpoint scores
4. Patient-rated hospital anxiety and depression scale
5. Covi Anxiety Scale
6. Raskin Depression Scale
Notes Supported by Wyeth-Ayerst Research
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
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3. Two parallel groups
4. Duration 28 weeks
5. Analysis: LOCF
Participants 1. Diagnosis: GAD (DSM-IV)




4. Sex: 59% females
5. Setting: outpatients
6. History: excluded major depression; any psychotic disorder; clinically significant psychi-
atric disorder other than GAD
Interventions 1. Placebo (N = 127)
2. Venlafaxine 75-150 mg/d (N = 124)
Outcomes 1. dropout rates
2. CGI scores
3. HAM -A scores
Notes Supported by Wyeth-Ayerst Research
Risk of bias
Bias Authors’ judgement Support for judgement




3. Four parallel groups (placebo, venlafaxine 37.5, 75 and 150 mg/d)
4. Duration: 24 weeks
5. Analysis: LOCF
Participants 1. Diagnosis: GAD (DSM-IV)
2. N = 541
3. Age (mean and SD):
placebo = 46.1(range 18-86); velnafaxine 37.5 mg/d = 45.4 (range 19-79); venlafaxine 75
mg/d = 45.4(range 19-79); venlafaxine 150 mg/d = 45 (range 20-82);
Sex: placebo = 58% females; venlafaxine 37.5 mg/d = 57 % females; venlafaxine 75 mg/d
= 62 % females; venlafaxine 150 mg/d = 65 % females
Setting: outpatients
History:
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Hackett 1999 (Continued)
excluded psychiatric disorder other than GAD
Interventions 1. Placebo (N = 130)
2. Venlafaxine 37.5 mg/d (N = 140)
3. Venlafaxine 75 mg/d (N=134)
4. Venlafaxine 150 mg/d (N = 137)
Outcomes 1. dropout rates
2. CGI scores
3. HAM -A scores
4. Hospital anxiety and depression scale
5. The brief scale for anxiety
6. Self-rated social adjustment scale
7. Physician Withdrawal Checklist
Notes Supported by Wyeth-Ayerst Research
Risk of bias
Bias Authors’ judgement Support for judgement




3. Two parallel groups
4. Duration: 8 weeks
5. Analysis: ITT
Participants 1. Diagnosis: GAD (DSM-IV)
2. N = 331
3. Age:
placebo = 41.3(range 19-80)
paroxetine = 39.7 (range 19-69)
4. Sex: 66% females
5. Setting: outpatients
6. History: DSM-IV criteria for GAD, MINI-International Neuropsychiatric Interview ,
Excluded any other Axis I disorder
Interventions 1. Placebo (N = 163)
2. Paroxetine (N = 161)
Outcomes 1. dropout rates
2. CGI scores
3. HAM -A scores
4. Sheehan disability scale scores
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Pollack 2001 (Continued)
Notes Supported by Wyeth-Ayerst Research
Risk of bias
Bias Authors’ judgement Support for judgement




3. Four parallel groups (placebo, imipramine, trazodone, diazepam)
4. Duration: 8 weeks
5. Analysis: LOCF
Participants 1. Diagnosis: GAD (DSM-III)




History: GAD without other significant axis I diagnoses
Interventions 1. Placebo (N = 55)
2. Imipramine +/- 143 mg/d (N = 58)
3. trazodone +/- 225 mg/d (N = 61)
4. diazepam +/- 26 mg/d (N = 56)
Outcomes 1. dropout rates
2. CGI scores
3. HAM -A scores
Notes Supported by an US Public Health Grant
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
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3. Four parallel groups
4. Duration 8 weeks
5. Analysis: LOCF
Participants 1. Diagnosis: GAD (DSM-IV)
2. N = 377
3. Age:
placebo = 40.9(11.3)
venlafaxine 75 = 40.4(12.8)
venlafaxine 150 = 39.6(11.9)
venlafaxine 225 = 42.4(12.3)
4. Sex: 56% females
5. Setting: outpatients
6. History: DSM-IV criteria for GAD but not for Major Depressive Disorder
Interventions 1. Placebo (N = 96)
2. Venlafaxine 75 mg/d (N = 86)
3. Venlafaxine 150 mg/d (N = 81)
4. Venlafaxine 225 mg/d (N = 86)
Outcomes 1. dropout rates
2. CGI scores
3. HAM -A scores
4. Hospital Anxiety and Depression Scale anxiety subscale
Notes Supported by Wyeth-Ayerst Laboratories
Risk of bias
Bias Authors’ judgement Support for judgement




3. Duration: 8 weeks
4. Three parallel groups
5. Analysis: Repeated measures ANOVA (interaction drug X time)
Participants 1. Diagnosis: GAD (DSM-IV)
2. N = 81;
3. Age: imipramine group (mean and SD) = 37.6(9.1)
paroxetine 20 mg/d group = 35.3(9.3)
4. Sex: 57 % females
13Antidepressants for generalised anxiety disorder (GAD) (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Rocca 1997 (Continued)
5. Setting: outpatients
6. History: DSM-IV GAD (other Axis I diagnosis were excluded)
Interventions 1. Imipramine 50-100 mg/d (N = 26)
2. Paroxetine 20 mg/d (N = 30)
3. Chlordesmethyldiazepam 4.2(1.1) mg/d (N = 25)
Outcomes 1. dropout rates
2. CGI scores
3. HAM-A scores
Notes Funding not specified
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Rynn 2000
Methods 1. Randomized (random study assignments were made in groups of four patients)
2. Double blind
3. Duration: 9 weeks
4. Analysis: Repeated measures analysis of covariance (with baseline score on CGI as co-
variate)
Participants 1. Diagnosis: GAD (DSM-IV, according to the Anxiety Disorders Interview Schedule for
children - Revised)
2. N = 22;
3. Age: 5 to 17
4. Sex: 33% female
5. Setting: outpatients
6. History: Included DSM-IV GAD patients; excluded ustable or acute medical conditions
and additional axis I or II disorders (apart from subsyndromal symptoms of separation
anxiety)
Interventions 1. Placebo (N = 11)
2. Sertraline (N = 11)
Outcomes 1. dropout rates
2. CGI scores
3. HAM-A scores
Notes Supported by the mood and Anxiety Disorders Section, Department of Psychiatry, Uni-
versity of pennsylvannia, and by NIMH grants MH-14651 and MH-011819
Risk of bias
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Rynn 2000 (Continued)
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Hedges 1996 Open trial, non randomized
Johnstone 1980 a Included patients suffering from depressive and anxious neurosis
Lipman 1986 Included patients with anxiety neurosis as well as patients suffering from either hysterical or phobic neurosis
Rickels 2000 a This trial was designed to assess the effectiveness of imipramine and buspirone in facilitating benzodiazepine
discontinuation in patients suffering from GAD
Wingerson 1992 Open trial, non randomized
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D A T A A N D A N A L Y S E S
Comparison 1. Antidepressants vs placebo




participants Statistical method Effect size
1 No treatment response 4 1056 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.60, 0.82]
2 Number of people who dropped
out
6 1951 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.73, 1.24]
3 Side effects 6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Drowsiness 1 174 Risk Ratio (M-H, Random, 95% CI) 4.89 [2.41, 9.90]
3.2 Dizziness 5 1623 Risk Ratio (M-H, Random, 95% CI) 1.84 [1.26, 2.69]
3.3 Confusion 1 174 Risk Ratio (M-H, Random, 95% CI) 12.02 [1.67, 86.30]
3.4 Tremors 1 174 Risk Ratio (M-H, Random, 95% CI) 14.47 [0.88, 237.48]
3.5 Dry mouth 5 1623 Risk Ratio (M-H, Random, 95% CI) 2.96 [2.19, 4.01]
3.6 Constipation 4 1290 Risk Ratio (M-H, Random, 95% CI) 3.48 [2.10, 5.78]
3.7 Nausea 5 1773 Risk Ratio (M-H, Random, 95% CI) 2.83 [2.16, 3.72]
3.8 Insomnia 1 350 Risk Ratio (M-H, Random, 95% CI) 1.94 [1.15, 3.28]
3.9 Somnolence 3 922 Risk Ratio (M-H, Random, 95% CI) 2.59 [1.85, 3.64]
3.10 Asthenia 3 981 Risk Ratio (M-H, Random, 95% CI) 1.89 [1.33, 2.70]
3.11 Anorexia 2 601 Risk Ratio (M-H, Random, 95% CI) 9.04 [2.57, 31.77]
3.12 Nervousness 1 350 Risk Ratio (M-H, Random, 95% CI) 1.92 [0.88, 4.17]
3.13 Flatulence 1 350 Risk Ratio (M-H, Random, 95% CI) 8.87 [0.53, 149.15]
3.14 Sexual dysfunction 3 925 Risk Ratio (M-H, Random, 95% CI) 5.66 [2.98, 10.73]
3.15 Sweating 2 792 Risk Ratio (M-H, Random, 95% CI) 2.92 [1.46, 5.86]
3.16 Infection 1 541 Risk Ratio (M-H, Random, 95% CI) 2.06 [0.73, 5.78]
3.17 Paraesthesiae 1 541 Risk Ratio (M-H, Random, 95% CI) 2.06 [0.47, 8.99]
Comparison 2. Imipramine vs placebo




participants Statistical method Effect size
1 No treatment response 1 113 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.50, 0.91]
2 Number of people who dropped
out
1 113 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.41, 1.24]
3 Specific side effects 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Drowsiness 1 113 Risk Ratio (M-H, Random, 95% CI) 4.06 [1.95, 8.48]
3.2 Dizziness 1 113 Risk Ratio (M-H, Random, 95% CI) 3.48 [1.53, 7.93]
3.3 Confusion 1 113 Risk Ratio (M-H, Random, 95% CI) 7.59 [0.98, 58.69]
3.4 Tremors 1 113 Risk Ratio (M-H, Random, 95% CI) 18.03 [1.07, 302.62]
3.5 Dry mouth 1 113 Risk Ratio (M-H, Random, 95% CI) 40.78 [5.81, 286.03]
3.6 Constipation 1 113 Risk Ratio (M-H, Random, 95% CI) 3.22 [1.28, 8.14]
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Comparison 3. Venlafaxine vs placebo




participants Statistical method Effect size
1 No treatment response 2 558 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.46, 0.99]
2 Number of people who dropped
out
3 997 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.72, 1.02]
3 Specific side effects 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Nausea 4 1449 Risk Ratio (M-H, Random, 95% CI) 2.66 [2.01, 3.52]
3.2 Dizziness 4 1449 Risk Ratio (M-H, Random, 95% CI) 1.88 [1.20, 2.95]
3.3 Asthenia 2 657 Risk Ratio (M-H, Random, 95% CI) 1.53 [0.98, 2.38]
3.4 Dry mouth 4 1449 Risk Ratio (M-H, Random, 95% CI) 3.04 [2.07, 4.46]
3.5 Insomnia 1 350 Risk Ratio (M-H, Random, 95% CI) 1.94 [1.15, 3.28]
3.6 Constipation 2 792 Risk Ratio (M-H, Random, 95% CI) 2.75 [1.37, 5.53]
3.7 Somnolence 2 601 Risk Ratio (M-H, Random, 95% CI) 2.64 [1.62, 4.31]
3.8 Anorexia 2 601 Risk Ratio (M-H, Random, 95% CI) 9.04 [2.57, 31.77]
3.9 Sexual dysfunction 2 601 Risk Ratio (M-H, Random, 95% CI) 4.19 [1.53, 11.51]
3.10 Nervousness 1 350 Risk Ratio (M-H, Random, 95% CI) 1.92 [0.88, 4.17]
3.11 Flatulence 1 350 Risk Ratio (M-H, Random, 95% CI) 8.87 [0.53, 149.15]
3.12 Infection 1 541 Risk Ratio (M-H, Random, 95% CI) 2.06 [0.73, 5.78]
3.13 Paraesthesiae 1 541 Risk Ratio (M-H, Random, 95% CI) 2.06 [0.47, 8.99]
3.14 Sweating 1 541 Risk Ratio (M-H, Random, 95% CI) 2.40 [0.97, 5.98]
Comparison 4. Paroxetine vs placebo




participants Statistical method Effect size
1 No treatment response 1 324 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.56, 0.92]
2 Number of people who dropped
out
1 324 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.74, 1.78]
3 Specific side effects 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Asthenia 1 324 Risk Ratio (M-H, Random, 95% CI) 2.02 [1.18, 3.47]
3.2 Constipation 1 324 Risk Ratio (M-H, Random, 95% CI) 8.44 [2.60, 27.39]
3.3 Sexual dysfunction 1 324 Risk Ratio (M-H, Random, 95% CI) 6.92 [3.02, 15.84]
3.4 Nausea 1 324 Risk Ratio (M-H, Random, 95% CI) 4.15 [2.15, 8.00]
3.5 Somnolence 1 324 Risk Ratio (M-H, Random, 95% CI) 2.49 [1.28, 4.84]
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Comparison 5. Sertraline vs placebo (in children and adolescents)




participants Statistical method Effect size
1 No treatment response 1 22 Risk Ratio (M-H, Random, 95% CI) 0.10 [0.02, 0.65]
2 Number of people who dropped
out
1 22 Risk Ratio (M-H, Random, 95% CI) 0.5 [0.05, 4.75]
3 Specific side effects 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Dry mouth 1 22 Risk Ratio (M-H, Random, 95% CI) 2.0 [0.66, 6.04]
3.2 Drowsiness 1 22 Risk Ratio (M-H, Random, 95% CI) 1.75 [0.71, 4.31]
3.3 Leg spasms 1 22 Risk Ratio (M-H, Random, 95% CI) 4.0 [0.53, 30.33]
3.4 Restlessness 1 22 Risk Ratio (M-H, Random, 95% CI) 2.0 [0.66, 6.04]
3.5 Dizziness 1 22 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.08, 1.08]
3.6 Nausea 1 22 Risk Ratio (M-H, Random, 95% CI) 0.17 [0.02, 1.17]
3.7 Stomach pain 1 22 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.08, 1.08]
Comparison 6. Paroxetine vs imipramine




participants Statistical method Effect size
1 No treatment response 1 56 Risk Ratio (M-H, Random, 95% CI) 1.73 [0.31, 9.57]
2 Number of people who dropped
out
1 56 Risk Ratio (M-H, Random, 95% CI) 1.62 [0.58, 4.48]
3 Specific side effects 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Constipation 1 56 Risk Ratio (M-H, Random, 95% CI) 5.77 [1.39, 23.97]
3.2 Dizziness 1 56 Risk Ratio (M-H, Random, 95% CI) 3.46 [0.76, 15.70]
3.3 Dry mouth 1 56 Risk Ratio (M-H, Random, 95% CI) 8.65 [2.18, 34.36]
3.4 Nausea 1 56 Risk Ratio (M-H, Random, 95% CI) 0.19 [0.05, 0.78]
3.5 Nervousness 1 56 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.21, 3.52]
3.6 Drowsiness 1 56 Risk Ratio (M-H, Random, 95% CI) 11.54 [1.58, 84.19]
3.7 Tiredness 1 56 Risk Ratio (M-H, Random, 95% CI) 0.38 [0.08, 1.74]
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Analysis 1.1. Comparison 1 Antidepressants vs placebo, Outcome 1 No treatment response.
Review: Antidepressants for generalised anxiety disorder (GAD)
Comparison: 1 Antidepressants vs placebo
Outcome: 1 No treatment response








Davidson 1999 a 105/203 66/104 29.1 % 0.82 [ 0.67, 0.99 ]
Gelenberg 2000 47/124 87/127 22.3 % 0.55 [ 0.43, 0.71 ]
Pollack 2001 61/161 86/163 23.3 % 0.72 [ 0.56, 0.92 ]
Rickels 1993 64/119 41/55 25.3 % 0.72 [ 0.57, 0.91 ]
Total (95% CI) 607 449 100.0 % 0.70 [ 0.60, 0.82 ]
Total events: 277 (Antidepressants), 280 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 5.67, df = 3 (P = 0.13); I2 =47%
Test for overall effect: Z = 4.36 (P = 0.000013)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Antidepressants vs placebo, Outcome 2 Number of people who dropped out.
Review: Antidepressants for generalised anxiety disorder (GAD)
Comparison: 1 Antidepressants vs placebo
Outcome: 2 Number of people who dropped out








Davidson 1999 a 84/203 36/104 17.9 % 1.20 [ 0.88, 1.63 ]
Gelenberg 2000 73/124 87/127 21.3 % 0.86 [ 0.71, 1.04 ]
Hackett 1999 102/411 45/130 18.5 % 0.72 [ 0.54, 0.96 ]
Pollack 2001 34/161 30/163 14.3 % 1.15 [ 0.74, 1.78 ]
Rickels 1993 27/121 23/58 13.8 % 0.56 [ 0.36, 0.89 ]
Rickels 2000 b 83/253 19/96 14.3 % 1.66 [ 1.07, 2.57 ]
Total (95% CI) 1273 678 100.0 % 0.95 [ 0.73, 1.24 ]
Total events: 403 (Antidepressant), 240 (Placebo)
Heterogeneity: Tau2 = 0.07; Chi2 = 18.75, df = 5 (P = 0.002); I2 =73%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Antidepressants vs placebo, Outcome 3 Side effects.
Review: Antidepressants for generalised anxiety disorder (GAD)
Comparison: 1 Antidepressants vs placebo
Outcome: 3 Side effects









Rickels 1993 74/119 7/55 100.0 % 4.89 [ 2.41, 9.90 ]
Subtotal (95% CI) 119 55 100.0 % 4.89 [ 2.41, 9.90 ]
Total events: 74 (Antidepressants), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.40 (P = 0.000011)
2 Dizziness
Davidson 1999 a 38/203 14/104 21.3 % 1.39 [ 0.79, 2.45 ]
Gelenberg 2000 24/124 18/127 21.5 % 1.37 [ 0.78, 2.39 ]
Hackett 1999 68/411 14/130 22.2 % 1.54 [ 0.89, 2.64 ]
Rickels 1993 59/119 6/55 15.0 % 4.54 [ 2.09, 9.88 ]
Rickels 2000 b 61/253 11/97 20.1 % 2.13 [ 1.17, 3.87 ]
Subtotal (95% CI) 1110 513 100.0 % 1.84 [ 1.26, 2.69 ]
Total events: 250 (Antidepressants), 63 (Placebo)
Heterogeneity: Tau2 = 0.09; Chi2 = 8.02, df = 4 (P = 0.09); I2 =50%
Test for overall effect: Z = 3.15 (P = 0.0016)
3 Confusion
Rickels 1993 26/119 1/55 100.0 % 12.02 [ 1.67, 86.30 ]
Subtotal (95% CI) 119 55 100.0 % 12.02 [ 1.67, 86.30 ]
Total events: 26 (Antidepressants), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.47 (P = 0.013)
4 Tremors
Rickels 1993 15/119 0/55 100.0 % 14.47 [ 0.88, 237.48 ]
Subtotal (95% CI) 119 55 100.0 % 14.47 [ 0.88, 237.48 ]
Total events: 15 (Antidepressants), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.87 (P = 0.061)
5 Dry mouth
Davidson 1999 a 40/203 5/104 11.4 % 4.10 [ 1.67, 10.07 ]
Gelenberg 2000 31/124 14/127 27.3 % 2.27 [ 1.27, 4.05 ]
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Hackett 1999 36/411 4/130 8.9 % 2.85 [ 1.03, 7.85 ]
Rickels 1993 80/119 13/55 38.1 % 2.84 [ 1.74, 4.65 ]
Rickels 2000 b 68/253 6/97 14.3 % 4.35 [ 1.95, 9.68 ]
Subtotal (95% CI) 1110 513 100.0 % 2.96 [ 2.19, 4.01 ]
Total events: 255 (Antidepressants), 42 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.31, df = 4 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 7.02 (P < 0.00001)
6 Constipation
Gelenberg 2000 14/124 4/127 21.2 % 3.58 [ 1.21, 10.59 ]
Hackett 1999 36/411 5/130 29.4 % 2.28 [ 0.91, 5.68 ]
Pollack 2001 25/161 3/163 18.0 % 8.44 [ 2.60, 27.39 ]
Rickels 1993 33/119 5/55 31.3 % 3.05 [ 1.26, 7.39 ]
Subtotal (95% CI) 815 475 100.0 % 3.48 [ 2.10, 5.78 ]
Total events: 108 (Antidepressants), 17 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.12, df = 3 (P = 0.37); I2 =4%
Test for overall effect: Z = 4.82 (P < 0.00001)
7 Nausea
Davidson 1999 a 78/203 14/104 19.7 % 2.85 [ 1.70, 4.79 ]
Gelenberg 2000 58/124 27/127 28.9 % 2.20 [ 1.50, 3.23 ]
Hackett 1999 98/411 14/130 19.3 % 2.21 [ 1.31, 3.74 ]
Pollack 2001 41/161 10/163 13.7 % 4.15 [ 2.15, 8.00 ]
Rickels 2000 b 128/253 12/97 18.3 % 4.09 [ 2.37, 7.04 ]
Subtotal (95% CI) 1152 621 100.0 % 2.83 [ 2.16, 3.72 ]
Total events: 403 (Antidepressants), 77 (Placebo)
Heterogeneity: Tau2 = 0.03; Chi2 = 5.67, df = 4 (P = 0.23); I2 =29%
Test for overall effect: Z = 7.50 (P < 0.00001)
8 Insomnia
Rickels 2000 b 71/253 14/97 100.0 % 1.94 [ 1.15, 3.28 ]
Subtotal (95% CI) 253 97 100.0 % 1.94 [ 1.15, 3.28 ]
Total events: 71 (Antidepressants), 14 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.49 (P = 0.013)
9 Somnolence
Gelenberg 2000 46/124 14/127 38.7 % 3.37 [ 1.95, 5.80 ]
Pollack 2001 27/161 11/161 25.9 % 2.45 [ 1.26, 4.78 ]
Rickels 2000 b 64/253 12/96 35.4 % 2.02 [ 1.14, 3.58 ]
Subtotal (95% CI) 538 384 100.0 % 2.59 [ 1.85, 3.64 ]
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Total events: 137 (Antidepressants), 37 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.63, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 5.50 (P < 0.00001)
10 Asthenia
Davidson 1999 a 36/203 10/104 29.2 % 1.84 [ 0.95, 3.57 ]
Pollack 2001 34/161 17/163 43.6 % 2.02 [ 1.18, 3.47 ]
Rickels 2000 b 41/253 9/97 27.3 % 1.75 [ 0.88, 3.46 ]
Subtotal (95% CI) 617 364 100.0 % 1.89 [ 1.33, 2.70 ]
Total events: 111 (Antidepressants), 36 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.12, df = 2 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 3.51 (P = 0.00045)
11 Anorexia
Gelenberg 2000 14/124 0/127 20.0 % 29.70 [ 1.79, 492.46 ]
Rickels 2000 b 35/253 2/97 80.0 % 6.71 [ 1.65, 27.36 ]
Subtotal (95% CI) 377 224 100.0 % 9.04 [ 2.57, 31.77 ]
Total events: 49 (Antidepressants), 2 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.89, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 3.43 (P = 0.00060)
12 Nervousness
Rickels 2000 b 35/253 7/97 100.0 % 1.92 [ 0.88, 4.17 ]
Subtotal (95% CI) 253 97 100.0 % 1.92 [ 0.88, 4.17 ]
Total events: 35 (Antidepressants), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
13 Flatulence
Rickels 2000 b 11/253 0/97 100.0 % 8.87 [ 0.53, 149.15 ]
Subtotal (95% CI) 253 97 100.0 % 8.87 [ 0.53, 149.15 ]
Total events: 11 (Antidepressants), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
14 Sexual dysfunction
Gelenberg 2000 14/124 4/127 35.0 % 3.58 [ 1.21, 10.59 ]
Pollack 2001 41/161 6/163 59.8 % 6.92 [ 3.02, 15.84 ]
Rickels 2000 b 15/253 0/97 5.2 % 11.96 [ 0.72, 197.97 ]
Subtotal (95% CI) 538 387 100.0 % 5.66 [ 2.98, 10.73 ]
Total events: 70 (Antidepressants), 10 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.22, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 5.30 (P < 0.00001)
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Gelenberg 2000 15/124 4/127 41.8 % 3.84 [ 1.31, 11.25 ]
Hackett 1999 38/411 5/130 58.2 % 2.40 [ 0.97, 5.98 ]
Subtotal (95% CI) 535 257 100.0 % 2.92 [ 1.46, 5.86 ]
Total events: 53 (Antidepressants), 9 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.43, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 3.03 (P = 0.0025)
16 Infection
Hackett 1999 26/411 4/130 100.0 % 2.06 [ 0.73, 5.78 ]
Subtotal (95% CI) 411 130 100.0 % 2.06 [ 0.73, 5.78 ]
Total events: 26 (Antidepressants), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
17 Paraesthesiae
Hackett 1999 13/411 2/130 100.0 % 2.06 [ 0.47, 8.99 ]
Subtotal (95% CI) 411 130 100.0 % 2.06 [ 0.47, 8.99 ]
Total events: 13 (Antidepressants), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
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Analysis 2.1. Comparison 2 Imipramine vs placebo, Outcome 1 No treatment response.
Review: Antidepressants for generalised anxiety disorder (GAD)
Comparison: 2 Imipramine vs placebo
Outcome: 1 No treatment response








Rickels 1993 29/58 41/55 100.0 % 0.67 [ 0.50, 0.91 ]
Total (95% CI) 58 55 100.0 % 0.67 [ 0.50, 0.91 ]
Total events: 29 (Imipramine), 41 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.61 (P = 0.0091)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Imipramine vs placebo, Outcome 2 Number of people who dropped out.
Review: Antidepressants for generalised anxiety disorder (GAD)
Comparison: 2 Imipramine vs placebo
Outcome: 2 Number of people who dropped out








Rickels 1993 15/58 20/55 100.0 % 0.71 [ 0.41, 1.24 ]
Total (95% CI) 58 55 100.0 % 0.71 [ 0.41, 1.24 ]
Total events: 15 (Imipramine), 20 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Imipramine vs placebo, Outcome 3 Specific side effects.
Review: Antidepressants for generalised anxiety disorder (GAD)
Comparison: 2 Imipramine vs placebo
Outcome: 3 Specific side effects









Rickels 1993 30/58 7/55 100.0 % 4.06 [ 1.95, 8.48 ]
Subtotal (95% CI) 58 55 100.0 % 4.06 [ 1.95, 8.48 ]
Total events: 30 (Imipramine), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.74 (P = 0.00019)
2 Dizziness
Rickels 1993 22/58 6/55 100.0 % 3.48 [ 1.53, 7.93 ]
Subtotal (95% CI) 58 55 100.0 % 3.48 [ 1.53, 7.93 ]
Total events: 22 (Imipramine), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.96 (P = 0.0030)
3 Confusion
Rickels 1993 8/58 1/55 100.0 % 7.59 [ 0.98, 58.69 ]
Subtotal (95% CI) 58 55 100.0 % 7.59 [ 0.98, 58.69 ]
Total events: 8 (Imipramine), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.94 (P = 0.052)
4 Tremors
Rickels 1993 9/58 0/55 100.0 % 18.03 [ 1.07, 302.62 ]
Subtotal (95% CI) 58 55 100.0 % 18.03 [ 1.07, 302.62 ]
Total events: 9 (Imipramine), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.01 (P = 0.044)
5 Dry mouth
Rickels 1993 43/58 1/55 100.0 % 40.78 [ 5.81, 286.03 ]
Subtotal (95% CI) 58 55 100.0 % 40.78 [ 5.81, 286.03 ]
Total events: 43 (Imipramine), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.73 (P = 0.00019)
6 Constipation
Rickels 1993 17/58 5/55 100.0 % 3.22 [ 1.28, 8.14 ]
Subtotal (95% CI) 58 55 100.0 % 3.22 [ 1.28, 8.14 ]
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Total events: 17 (Imipramine), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.48 (P = 0.013)
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Analysis 3.1. Comparison 3 Venlafaxine vs placebo, Outcome 1 No treatment response.
Review: Antidepressants for generalised anxiety disorder (GAD)
Comparison: 3 Venlafaxine vs placebo
Outcome: 1 No treatment response








Davidson 1999 a 105/203 66/104 52.2 % 0.82 [ 0.67, 0.99 ]
Gelenberg 2000 47/124 87/127 47.8 % 0.55 [ 0.43, 0.71 ]
Total (95% CI) 327 231 100.0 % 0.68 [ 0.46, 0.99 ]
Total events: 152 (Venlafaxine), 153 (Placebo)
Heterogeneity: Tau2 = 0.06; Chi2 = 5.69, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 1.99 (P = 0.046)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Venlafaxine vs placebo, Outcome 2 Number of people who dropped out.
Review: Antidepressants for generalised anxiety disorder (GAD)
Comparison: 3 Venlafaxine vs placebo
Outcome: 2 Number of people who dropped out








Davidson 1999 a 46/101 46/104 25.3 % 1.03 [ 0.76, 1.39 ]
Gelenberg 2000 73/124 87/127 47.5 % 0.86 [ 0.71, 1.04 ]
Hackett 1999 102/411 45/130 27.1 % 0.72 [ 0.54, 0.96 ]
Total (95% CI) 636 361 100.0 % 0.86 [ 0.72, 1.02 ]
Total events: 221 (Venlafaxine), 178 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 2.87, df = 2 (P = 0.24); I2 =30%
Test for overall effect: Z = 1.73 (P = 0.083)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
28Antidepressants for generalised anxiety disorder (GAD) (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.3. Comparison 3 Venlafaxine vs placebo, Outcome 3 Specific side effects.
Review: Antidepressants for generalised anxiety disorder (GAD)
Comparison: 3 Venlafaxine vs placebo
Outcome: 3 Specific side effects









Davidson 1999 a 78/203 14/104 22.5 % 2.85 [ 1.70, 4.79 ]
Gelenberg 2000 58/124 27/127 34.5 % 2.20 [ 1.50, 3.23 ]
Hackett 1999 98/411 14/130 22.1 % 2.21 [ 1.31, 3.74 ]
Rickels 2000 b 128/253 12/97 20.9 % 4.09 [ 2.37, 7.04 ]
Subtotal (95% CI) 991 458 100.0 % 2.66 [ 2.01, 3.52 ]
Total events: 362 (Treatment), 67 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 4.00, df = 3 (P = 0.26); I2 =25%
Test for overall effect: Z = 6.86 (P < 0.00001)
2 Dizziness
Davidson 1999 a 38/203 14/104 28.0 % 1.39 [ 0.79, 2.45 ]
Gelenberg 2000 24/124 18/127 28.3 % 1.37 [ 0.78, 2.39 ]
Hackett 1999 68/411 5/130 17.1 % 4.30 [ 1.77, 10.44 ]
Rickels 2000 b 61/253 11/97 26.6 % 2.13 [ 1.17, 3.87 ]
Subtotal (95% CI) 991 458 100.0 % 1.88 [ 1.20, 2.95 ]
Total events: 191 (Treatment), 48 (Control)
Heterogeneity: Tau2 = 0.11; Chi2 = 6.07, df = 3 (P = 0.11); I2 =51%
Test for overall effect: Z = 2.74 (P = 0.0061)
3 Asthenia
Davidson 1999 a 36/203 10/104 45.2 % 1.84 [ 0.95, 3.57 ]
Rickels 2000 b 41/253 12/97 54.8 % 1.31 [ 0.72, 2.38 ]
Subtotal (95% CI) 456 201 100.0 % 1.53 [ 0.98, 2.38 ]
Total events: 77 (Treatment), 22 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.57, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.88 (P = 0.061)
4 Dry mouth
Davidson 1999 a 40/203 5/104 18.4 % 4.10 [ 1.67, 10.07 ]
Gelenberg 2000 31/124 14/127 44.1 % 2.27 [ 1.27, 4.05 ]
Hackett 1999 36/411 4/130 14.4 % 2.85 [ 1.03, 7.85 ]
Rickels 2000 b 68/253 6/97 23.1 % 4.35 [ 1.95, 9.68 ]
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Subtotal (95% CI) 991 458 100.0 % 3.04 [ 2.07, 4.46 ]
Total events: 175 (Treatment), 29 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.27, df = 3 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 5.65 (P < 0.00001)
5 Insomnia
Rickels 2000 b 71/253 14/97 100.0 % 1.94 [ 1.15, 3.28 ]
Subtotal (95% CI) 253 97 100.0 % 1.94 [ 1.15, 3.28 ]
Total events: 71 (Treatment), 14 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.49 (P = 0.013)
6 Constipation
Gelenberg 2000 14/124 4/127 41.6 % 3.58 [ 1.21, 10.59 ]
Hackett 1999 36/411 5/130 58.4 % 2.28 [ 0.91, 5.68 ]
Subtotal (95% CI) 535 257 100.0 % 2.75 [ 1.37, 5.53 ]
Total events: 50 (Treatment), 9 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.39, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 2.84 (P = 0.0045)
7 Somnolence
Gelenberg 2000 46/124 14/127 51.5 % 3.37 [ 1.95, 5.80 ]
Rickels 2000 b 64/253 12/97 48.5 % 2.04 [ 1.16, 3.62 ]
Subtotal (95% CI) 377 224 100.0 % 2.64 [ 1.62, 4.31 ]
Total events: 110 (Treatment), 26 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 1.53, df = 1 (P = 0.22); I2 =35%
Test for overall effect: Z = 3.90 (P = 0.000096)
8 Anorexia
Gelenberg 2000 14/124 0/127 20.0 % 29.70 [ 1.79, 492.46 ]
Rickels 2000 b 35/253 2/97 80.0 % 6.71 [ 1.65, 27.36 ]
Subtotal (95% CI) 377 224 100.0 % 9.04 [ 2.57, 31.77 ]
Total events: 49 (Treatment), 2 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.89, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 3.43 (P = 0.00060)
9 Sexual dysfunction
Gelenberg 2000 14/124 4/127 87.0 % 3.58 [ 1.21, 10.59 ]
Rickels 2000 b 15/253 0/97 13.0 % 11.96 [ 0.72, 197.97 ]
Subtotal (95% CI) 377 224 100.0 % 4.19 [ 1.53, 11.51 ]
Total events: 29 (Treatment), 4 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.70, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 2.78 (P = 0.0055)
10 Nervousness
Rickels 2000 b 35/253 7/97 100.0 % 1.92 [ 0.88, 4.17 ]
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Subtotal (95% CI) 253 97 100.0 % 1.92 [ 0.88, 4.17 ]
Total events: 35 (Treatment), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
11 Flatulence
Rickels 2000 b 11/253 0/97 100.0 % 8.87 [ 0.53, 149.15 ]
Subtotal (95% CI) 253 97 100.0 % 8.87 [ 0.53, 149.15 ]
Total events: 11 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
12 Infection
Hackett 1999 26/411 4/130 100.0 % 2.06 [ 0.73, 5.78 ]
Subtotal (95% CI) 411 130 100.0 % 2.06 [ 0.73, 5.78 ]
Total events: 26 (Treatment), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
13 Paraesthesiae
Hackett 1999 13/411 2/130 100.0 % 2.06 [ 0.47, 8.99 ]
Subtotal (95% CI) 411 130 100.0 % 2.06 [ 0.47, 8.99 ]
Total events: 13 (Treatment), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
14 Sweating
Hackett 1999 38/411 5/130 100.0 % 2.40 [ 0.97, 5.98 ]
Subtotal (95% CI) 411 130 100.0 % 2.40 [ 0.97, 5.98 ]
Total events: 38 (Treatment), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.059)
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Analysis 4.1. Comparison 4 Paroxetine vs placebo, Outcome 1 No treatment response.
Review: Antidepressants for generalised anxiety disorder (GAD)
Comparison: 4 Paroxetine vs placebo
Outcome: 1 No treatment response








Pollack 2001 61/161 86/163 100.0 % 0.72 [ 0.56, 0.92 ]
Total (95% CI) 161 163 100.0 % 0.72 [ 0.56, 0.92 ]
Total events: 61 (Treatment), 86 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.64 (P = 0.0082)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Paroxetine vs placebo, Outcome 2 Number of people who dropped out.
Review: Antidepressants for generalised anxiety disorder (GAD)
Comparison: 4 Paroxetine vs placebo
Outcome: 2 Number of people who dropped out








Pollack 2001 34/161 30/163 100.0 % 1.15 [ 0.74, 1.78 ]
Total (95% CI) 161 163 100.0 % 1.15 [ 0.74, 1.78 ]
Total events: 34 (Treatment), 30 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 Paroxetine vs placebo, Outcome 3 Specific side effects.
Review: Antidepressants for generalised anxiety disorder (GAD)
Comparison: 4 Paroxetine vs placebo
Outcome: 3 Specific side effects









Pollack 2001 34/161 17/163 100.0 % 2.02 [ 1.18, 3.47 ]
Subtotal (95% CI) 161 163 100.0 % 2.02 [ 1.18, 3.47 ]
Total events: 34 (Treatment), 17 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.56 (P = 0.010)
2 Constipation
Pollack 2001 25/161 3/163 100.0 % 8.44 [ 2.60, 27.39 ]
Subtotal (95% CI) 161 163 100.0 % 8.44 [ 2.60, 27.39 ]
Total events: 25 (Treatment), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.55 (P = 0.00039)
3 Sexual dysfunction
Pollack 2001 41/161 6/163 100.0 % 6.92 [ 3.02, 15.84 ]
Subtotal (95% CI) 161 163 100.0 % 6.92 [ 3.02, 15.84 ]
Total events: 41 (Treatment), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.58 (P < 0.00001)
4 Nausea
Pollack 2001 41/161 10/163 100.0 % 4.15 [ 2.15, 8.00 ]
Subtotal (95% CI) 161 163 100.0 % 4.15 [ 2.15, 8.00 ]
Total events: 41 (Treatment), 10 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.25 (P = 0.000021)
5 Somnolence
Pollack 2001 27/161 11/163 100.0 % 2.49 [ 1.28, 4.84 ]
Subtotal (95% CI) 161 163 100.0 % 2.49 [ 1.28, 4.84 ]
Total events: 27 (Treatment), 11 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.68 (P = 0.0074)
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Analysis 5.1. Comparison 5 Sertraline vs placebo (in children and adolescents), Outcome 1 No treatment
response.
Review: Antidepressants for generalised anxiety disorder (GAD)
Comparison: 5 Sertraline vs placebo (in children and adolescents)
Outcome: 1 No treatment response








Rynn 2000 1/11 10/11 100.0 % 0.10 [ 0.02, 0.65 ]
Total (95% CI) 11 11 100.0 % 0.10 [ 0.02, 0.65 ]
Total events: 1 (Treatment), 10 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.40 (P = 0.016)
Test for subgroup differences: Not applicable
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Analysis 5.2. Comparison 5 Sertraline vs placebo (in children and adolescents), Outcome 2 Number of
people who dropped out.
Review: Antidepressants for generalised anxiety disorder (GAD)
Comparison: 5 Sertraline vs placebo (in children and adolescents)
Outcome: 2 Number of people who dropped out








Rynn 2000 1/11 2/11 100.0 % 0.50 [ 0.05, 4.75 ]
Total (95% CI) 11 11 100.0 % 0.50 [ 0.05, 4.75 ]
Total events: 1 (Treatment), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Not applicable
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Analysis 5.3. Comparison 5 Sertraline vs placebo (in children and adolescents), Outcome 3 Specific side
effects.
Review: Antidepressants for generalised anxiety disorder (GAD)
Comparison: 5 Sertraline vs placebo (in children and adolescents)
Outcome: 3 Specific side effects









Rynn 2000 6/11 3/11 100.0 % 2.00 [ 0.66, 6.04 ]
Subtotal (95% CI) 11 11 100.0 % 2.00 [ 0.66, 6.04 ]
Total events: 6 (Treatment), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
2 Drowsiness
Rynn 2000 7/11 4/11 100.0 % 1.75 [ 0.71, 4.31 ]
Subtotal (95% CI) 11 11 100.0 % 1.75 [ 0.71, 4.31 ]
Total events: 7 (Treatment), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
3 Leg spasms
Rynn 2000 4/11 1/11 100.0 % 4.00 [ 0.53, 30.33 ]
Subtotal (95% CI) 11 11 100.0 % 4.00 [ 0.53, 30.33 ]
Total events: 4 (Treatment), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
4 Restlessness
Rynn 2000 6/11 3/11 100.0 % 2.00 [ 0.66, 6.04 ]
Subtotal (95% CI) 11 11 100.0 % 2.00 [ 0.66, 6.04 ]
Total events: 6 (Treatment), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
5 Dizziness
Rynn 2000 2/11 7/11 100.0 % 0.29 [ 0.08, 1.08 ]
Subtotal (95% CI) 11 11 100.0 % 0.29 [ 0.08, 1.08 ]
Total events: 2 (Treatment), 7 (Control)
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Test for overall effect: Z = 1.85 (P = 0.065)
6 Nausea
Rynn 2000 1/11 6/11 100.0 % 0.17 [ 0.02, 1.17 ]
Subtotal (95% CI) 11 11 100.0 % 0.17 [ 0.02, 1.17 ]
Total events: 1 (Treatment), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.81 (P = 0.071)
7 Stomach pain
Rynn 2000 2/11 7/11 100.0 % 0.29 [ 0.08, 1.08 ]
Subtotal (95% CI) 11 11 100.0 % 0.29 [ 0.08, 1.08 ]
Total events: 2 (Treatment), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.85 (P = 0.065)
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Analysis 6.1. Comparison 6 Paroxetine vs imipramine, Outcome 1 No treatment response.
Review: Antidepressants for generalised anxiety disorder (GAD)
Comparison: 6 Paroxetine vs imipramine
Outcome: 1 No treatment response








Rocca 1997 3/26 2/30 100.0 % 1.73 [ 0.31, 9.57 ]
Total (95% CI) 26 30 100.0 % 1.73 [ 0.31, 9.57 ]
Total events: 3 (Imipramine), 2 (Paroxetine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
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Analysis 6.2. Comparison 6 Paroxetine vs imipramine, Outcome 2 Number of people who dropped out.
Review: Antidepressants for generalised anxiety disorder (GAD)
Comparison: 6 Paroxetine vs imipramine
Outcome: 2 Number of people who dropped out








Rocca 1997 7/26 5/30 100.0 % 1.62 [ 0.58, 4.48 ]
Total (95% CI) 26 30 100.0 % 1.62 [ 0.58, 4.48 ]
Total events: 7 (Imipramine), 5 (Paroxetine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 6.3. Comparison 6 Paroxetine vs imipramine, Outcome 3 Specific side effects.
Review: Antidepressants for generalised anxiety disorder (GAD)
Comparison: 6 Paroxetine vs imipramine
Outcome: 3 Specific side effects









Rocca 1997 10/26 2/30 100.0 % 5.77 [ 1.39, 23.97 ]
Subtotal (95% CI) 26 30 100.0 % 5.77 [ 1.39, 23.97 ]
Total events: 10 (Imipramine), 2 (Paroxetine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.41 (P = 0.016)
2 Dizziness
Rocca 1997 6/26 2/30 100.0 % 3.46 [ 0.76, 15.70 ]
Subtotal (95% CI) 26 30 100.0 % 3.46 [ 0.76, 15.70 ]
Total events: 6 (Imipramine), 2 (Paroxetine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
3 Dry mouth
Rocca 1997 15/26 2/30 100.0 % 8.65 [ 2.18, 34.36 ]
Subtotal (95% CI) 26 30 100.0 % 8.65 [ 2.18, 34.36 ]
Total events: 15 (Imipramine), 2 (Paroxetine)
Heterogeneity: not applicable
Test for overall effect: Z = 3.07 (P = 0.0022)
4 Nausea
Rocca 1997 2/26 12/30 100.0 % 0.19 [ 0.05, 0.78 ]
Subtotal (95% CI) 26 30 100.0 % 0.19 [ 0.05, 0.78 ]
Total events: 2 (Imipramine), 12 (Paroxetine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.31 (P = 0.021)
5 Nervousness
Rocca 1997 3/26 4/30 100.0 % 0.87 [ 0.21, 3.52 ]
Subtotal (95% CI) 26 30 100.0 % 0.87 [ 0.21, 3.52 ]
Total events: 3 (Imipramine), 4 (Paroxetine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
6 Drowsiness
Rocca 1997 10/26 1/30 100.0 % 11.54 [ 1.58, 84.19 ]
Subtotal (95% CI) 26 30 100.0 % 11.54 [ 1.58, 84.19 ]
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Total events: 10 (Imipramine), 1 (Paroxetine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.41 (P = 0.016)
7 Tiredness
Rocca 1997 2/26 6/30 100.0 % 0.38 [ 0.08, 1.74 ]
Subtotal (95% CI) 26 30 100.0 % 0.38 [ 0.08, 1.74 ]
Total events: 2 (Imipramine), 6 (Paroxetine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.22)
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W H A T ’ S N E W
Last assessed as up-to-date: 20 January 2003.
Date Event Description
1 November 2008 Amended Converted to new review format.
H I S T O R Y
Protocol first published: Issue 4, 1999
Review first published: Issue 2, 2002
Date Event Description
21 January 2003 New citation required and conclusions have changed Substantive amendment
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D E C L A R A T I O N S O F I N T E R E S T
MSL took up a position with Eli Lilly in 2003.
Please note that the current version of this review contravenes Cochrane’s commercial sponsorship policy (revised 2014). The protocol
for this review is being re-written and publication of the new review is scheduled for 2016/17.




• No sources of support supplied
N O T E S
This review is to be passed onto a new group of authors.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antidepressive Agents [∗therapeutic use]; Anxiety Disorders [∗drug therapy]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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